Glusod (Empagliflozin)

Glusod (empagliflozin) is indicated for the management of hyperglycemia in adults with type 2 diabetes mellitus, often in combination with diet and exercise.

• As monotherapy when metformin is contraindicated or insufficient.
• Combined with metformin when additional glycemic control is needed.
• Used with other antihyperglycemic agents such as DPP‑4 inhibitors, GLP‑1 receptor agonists, or insulin.
• May be considered in patients with established cardiovascular disease to reduce risk of cardiovascular death.
• Occasionally prescribed for off‑label renal protection under specialist supervision (note: off‑label use varies by jurisdiction).

The safety profile of Glusod reflects the pharmacology of SGLT2 inhibition; side effects are reported across clinical studies and post‑marketing experience.

Common

• Increased urinary frequency and volume, which may lead to nocturia.
• Genital yeast infections, particularly vulvovaginal candidiasis in women and balanitis in men.
• Mild to moderate urinary tract infections presenting with dysuria or urgency.
• Sensations of thirst or dry mouth, often related to osmotic diuresis.

Serious

• Euglycemic diabetic ketoacidosis, a rare but potentially life‑threatening metabolic complication.
• Acute kidney injury or a rapid decline in renal function, especially in patients with pre‑existing kidney disease.
• Severe dehydration or hypotension resulting from excessive fluid loss.

When prescribing Glusod, clinicians should evaluate patient-specific factors and monitor for conditions that may be aggravated by SGLT2 inhibition.

• Assess renal function; avoid use in patients with eGFR below the approved threshold.
• Monitor for signs of volume depletion, especially in the elderly or those on diuretics.
• Evaluate risk of genital infections and counsel on hygiene measures.
• Review concomitant use of insulin or insulin secretagogues to prevent hypoglycemia.
• Consider ketoacidosis risk in patients with low carbohydrate intake or acute illness.
• Use caution during pregnancy or lactation; safety data are limited.

Glusod may interact with other medicines that affect glucose control, renal function, or fluid balance, requiring dose adjustments or monitoring.

Avoid

• Concomitant use with strong SGLT2 inhibitors or dual SGLT1/2 inhibitors, which can amplify glucose loss and dehydration.
• Combining with high‑dose loop diuretics in patients at risk of hypotension.

Use with caution

• Insulin or sulfonylureas, as additive hypoglycemia risk may require dose reduction.
• NSAIDs or ACE inhibitors that may affect renal perfusion.
• Anticoagulants, because dehydration could alter drug concentration.
• Alcohol, which can increase the risk of ketoacidosis.